Fasedienol Nasal Spray - Placebo Nasal Spray + Fasedienol Nasal Spray - Fasedienol Nasal Spray + Placebo Nasal Spray - Placebo Nasal Spray
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Social Anxiety Disorder
Conditions
Social Anxiety Disorder
Trial Timeline
Jan 9, 2025 → Dec 1, 2026
NCT ID
NCT06809179About Fasedienol Nasal Spray - Placebo Nasal Spray + Fasedienol Nasal Spray - Fasedienol Nasal Spray + Placebo Nasal Spray - Placebo Nasal Spray
Fasedienol Nasal Spray - Placebo Nasal Spray + Fasedienol Nasal Spray - Fasedienol Nasal Spray + Placebo Nasal Spray - Placebo Nasal Spray is a phase 2 stage product being developed by Vistagen Therapeutics for Social Anxiety Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06809179. Target conditions include Social Anxiety Disorder.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06809179 | Phase 2 | Recruiting |
Competing Products
20 competing products in Social Anxiety Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY686017 + paroxetine + placebo | Eli Lilly | Phase 2 | 52 |
| atomoxetine + placebo | Eli Lilly | Phase 2/3 | 65 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 52 |
| Cariprazine + Placebo | AbbVie | Approved | 85 |
| Quetiapine | AstraZeneca | Approved | 85 |
| quetiapine | AstraZeneca | Phase 3 | 77 |
| quetiapine | AstraZeneca | Phase 2/3 | 65 |
| Seroquel + Sugar Pill | AstraZeneca | Phase 3 | 77 |
| quetiapine | AstraZeneca | Approved | 85 |
| Pristiq + Placebo | Pfizer | Approved | 84 |
| Venlafaxine ER | Pfizer | Phase 3 | 76 |
| Ziprasidone + Sertraline | Pfizer | Phase 2 | 51 |
| Sertraline + Placebo | Pfizer | Approved | 84 |
| Nefazodone | Bristol Myers Squibb | Approved | 84 |
| Escitalopram | Lundbeck | Approved | 82 |
| Cipralex + Placebo | Lundbeck | Phase 2 | 49 |
| BHV-0223 + Placebo | Biohaven | Phase 2/3 | 60 |
| VQW-765 + Placebo | Vanda Pharmaceuticals | Phase 3 | 69 |
| PH94B | Vistagen Therapeutics | Phase 3 | 69 |
| PH94B Nasal Spray + Placebo Nasal Spray | Vistagen Therapeutics | Phase 3 | 69 |